March 30, 2020
CMS has issued important guidance ensuring that America’s clinical laboratories are prepared to respond to the threat of the 2019 Novel Coronavirus (COVID-19.) CMS is committed to taking critical steps to ensure America’s clinical laboratories are prepared to respond to the COVID-19 threat and other respiratory illnesses by implementing flexibility around requirements for a Clinical Laboratory Improvement Amendments (CLIA) certificate during public health emergencies. Click here to view the FAQ sheet.[download id=”1998″]